Roche, Celcuity Reveal Positive Breast Cancer Trial Results
- New data presented at the European Society for Medical oncology (ESMO) Congress suggests potential advancements in breast cancer treatment, with positive trial results for Celcuity's gedatolisib and Roche's...
- Both Celcuity and roche presented detailed data from their respective clinical trials at the ESMO Congress in Berlin on Saturday.
- Celcuity's gedatolisib trial results validated the initial positive topline outcomes announced in July, which significantly boosted the company's stock price.
“`html
Gedatolisib and Giredestrant Show Promise in Breast Cancer Treatment
Table of Contents
New data presented at the European Society for Medical oncology (ESMO) Congress suggests potential advancements in breast cancer treatment, with positive trial results for Celcuity’s gedatolisib and Roche’s giredestrant.
What Happened?
Both Celcuity and roche presented detailed data from their respective clinical trials at the ESMO Congress in Berlin on Saturday. Celcuity’s Phase 3 VIKTORIA-1 trial of gedatolisib demonstrated clinically meaningful improvements in progression-free survival (PFS) for patients with PIK3CA-wild-type breast cancer.Roche’s data indicated that giredestrant might potentially be effective in a wider range of patients than initially anticipated.
Gedatolisib: Unprecedented results in PIK3CA-Wild-Type Breast Cancer
Celcuity’s gedatolisib trial results validated the initial positive topline outcomes announced in July, which significantly boosted the company’s stock price. Analysts have described the findings as “unprecedented.” The detailed data showcased at ESMO further solidified these claims, demonstrating a considerable benefit in PFS for patients whose tumors do not have a PIK3CA mutation – a common genetic alteration in breast cancer.This is particularly meaningful as treatment options for this patient population are limited.
VIKTORIA-1 Trial Details
| Endpoint | Gedatolisib + Fulvestrant | Fulvestrant Alone | Hazard Ratio (HR) | p-value |
|---|---|---|---|---|
| progression-Free Survival (PFS) | 10.4 months | 6.2 months | 0.53 | <0.001 |
| Objective Response Rate (ORR) | 36.8% | 16.4% | 2.24 | <0.001 |
Data sourced from Celcuity’s press release.
Giredestrant: Expanding the Potential Patient Population
Roche’s giredestrant, a selective estrogen receptor degrader (SERD), demonstrated efficacy in a broader patient population than initially expected. While previously thought to be most effective in patients with ESR1 mutations, the new data suggests potential benefits for patients without these mutations as well. This broader applicability could significantly increase the number of patients who could benefit from the drug.
Expert Analysis
What Does This Mean for Patients?
The positive results from both trials offer hope for improved treatment options for patients with breast cancer. Gedatolis